The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.
T. Andre
Consultant or Advisory Role - Roche
Honoraria - Roche; Sanofi
E. Van Cutsem
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
H. Schmoll
Consultant or Advisory Role - Roche
Research Funding - Roche
J. Tabernero
Consultant or Advisory Role - Genentech; Roche
S. Clarke
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
M. J. Moore
No relevant relationships to disclose
D. Cunningham
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Amgen; Merck Serono; Roche; Sanofi
T. H. Cartwright
Consultant or Advisory Role - Genentech
Honoraria - Genentech
J. R. Hecht
No relevant relationships to disclose
F. Rivera
Consultant or Advisory Role - Roche
Research Funding - Roche
S. Im
No relevant relationships to disclose
G. Bodoky
Consultant or Advisory Role - Roche
R. Salazar
Honoraria - Roche
F. Maindrault-Goebel
No relevant relationships to disclose
E. Shmueli
No relevant relationships to disclose
E. Bajetta
Honoraria - Roche
M. Makrutzki
Employment or Leadership Position - Roche
A. Shang
Employment or Leadership Position - Roche
Stock Ownership - Roche
A. De Gramont
Consultant or Advisory Role - Roche (U)
P. M. Hoff
Consultant or Advisory Role - Roche